Show simple item record

dc.contributor.authorMetheny, Leland
dc.contributor.authorCallander, Natalie S
dc.contributor.authorHall, Aric C
dc.contributor.authorZhang, Mei-Jei
dc.contributor.authorBo-Subait, Khalid
dc.contributor.authorWang, Hai-Lin
dc.contributor.authorAgrawal, Vaibhav
dc.contributor.authorAl-Homsi, A Samer
dc.contributor.authorAssal, Amer
dc.contributor.authorBacher, Ulrike
dc.contributor.authorBeitinjaneh, Amer
dc.contributor.authorBejanyan, Nelli
dc.contributor.authorBhatt, Vijaya Raj
dc.contributor.authorBredeson, Chris
dc.contributor.authorByrne, Michael
dc.contributor.authorCairo, Mitchell
dc.contributor.authorCerny, Jan
dc.contributor.authorDeFilipp, Zachariah
dc.contributor.authorPerez, Miguel Angel Diaz
dc.contributor.authorFreytes, César O
dc.contributor.authorGanguly, Siddhartha
dc.contributor.authorGrunwald, Michael R
dc.contributor.authorHashmi, Shahrukh
dc.contributor.authorHildebrandt, Gerhard C
dc.contributor.authorInamoto, Yoshihiro
dc.contributor.authorKanakry, Christopher G
dc.contributor.authorKharfan-Dabaja, Mohamed A
dc.contributor.authorLazarus, Hillard M
dc.contributor.authorLee, Jong Wook
dc.contributor.authorNathan, Sunita
dc.contributor.authorNishihori, Taiga
dc.contributor.authorOlsson, Richard F
dc.contributor.authorRingdén, Olov
dc.contributor.authorRizzieri, David
dc.contributor.authorSavani, Bipin N
dc.contributor.authorSavoie, Mary Lynn
dc.contributor.authorSeo, Sachiko
dc.contributor.authorvan der Poel, Marjolein
dc.contributor.authorVerdonck, Leo F
dc.contributor.authorWagner, John L
dc.contributor.authorYared, Jean A
dc.contributor.authorHourigan, Christopher S
dc.contributor.authorKebriaei, Partow
dc.contributor.authorLitzow, Mark
dc.contributor.authorSandmaier, Brenda M
dc.contributor.authorSaber, Wael
dc.contributor.authorWeisdorf, Daniel
dc.contributor.authorde Lima, Marcos
dc.date.accessioned2022-01-19T14:18:08Z
dc.date.available2022-01-19T14:18:08Z
dc.date.issued2021-08-21
dc.identifier.urihttp://hdl.handle.net/10713/17546
dc.description.abstractPatients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myelogenous leukemia (t-AML), have a poor prognosis. An earlier Center for International Blood and Marrow Transplant Research (CIBMTR) analysis of 868 allogeneic hematopoietic cell transplantations (allo-HCTs) performed between 1990 and 2004 showed a 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%, respectively. Modern supportive care, graft-versus-host disease prophylaxis, and reduced-intensity conditioning (RIC) regimens have led to improved outcomes. Therefore, the CIBMTR analyzed 1531 allo-HCTs performed in adults with t-MDS (n = 759) or t-AML (n = 772) between and 2000 and 2014. The median age was 59 years (range, 18 to 74 years) for the patients with t-MDS and 52 years (range, 18 to 77 years) for those with t-AML. Twenty-four percent of patients with t-MDS and 11% of those with t-AML had undergone a previous autologous (auto-) HCT. A myeloablative conditioning (MAC) regimen was used in 49% of patients with t-MDS and 61% of patients with t-AML. Nonrelapse mortality at 5 years was 34% (95% confidence interval [CI], 30% to 37%) for patients with t-MDS and 34% (95% CI, 30% to 37%) for those with t-AML. Relapse rates at 5 years in the 2 groups were 46% (95% CI, 43% to 50%) and 43% (95% CI, 40% to 47%). Five-year OS and DFS were 27% (95% CI, 23% to 31%) and 19% (95% CI, 16% to 23%), respectively, for patients with t-MDS and 25% (95% CI, 22% to 28%) and 23% (95% CI, 20% to 26%), respectively, for those with t-AML. In multivariate analysis, OS and DFS were significantly better in young patients with low-risk t-MDS and those with t-AML undergoing HCT with MAC while in first complete remission, but worse for those with previous auto-HCT, higher-risk cytogenetics or Revised International Prognostic Scoring System score, and a partially matched unrelated donor. Relapse remains the major cause of treatment failure, with little improvement seen over the past 2 decades. These data mandate caution when recommending allo-HCT in these conditions and indicate the need for more effective antineoplastic approaches before and after allo-HCT.en_US
dc.description.urihttps://doi.org/10.1016/j.jtct.2021.08.010en_US
dc.language.isoenen_US
dc.publisherElsevier Inc.en_US
dc.relation.ispartofTransplantation and Cellular Therapyen_US
dc.rightsCopyright © 2021. Published by Elsevier Inc.en_US
dc.subjectAcute myelogenous leukemiaen_US
dc.subjectAllogeneic transplantationen_US
dc.subjectMyelodysplasiaen_US
dc.titleAllogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults.en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jtct.2021.08.010
dc.identifier.pmid34428556
dc.source.journaltitleTransplantation and cellular therapy
dc.source.volume27
dc.source.issue11
dc.source.beginpage923.e1
dc.source.endpage923.e12
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record